Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Says product sales in the year ended June 30, more than doubled to GBP4.6 million from GBP2.3 million the previous year. Revenue in the year totals GBP4.7 million including licensing income of GBP600,000, up from GBP4.4 million the previous year, including licensing income of GBP2.1 million.
"We are pleased to have delivered revenues in line with current expectations, reflecting both continued growth in Alkindi as well as the initial roll out of Efmody, primarily in Germany," said Interim Chief Executive Officer, Richard Bungay.
Alkindi sales grew 61% year-on-year to GBP3.7 million.
The firm will report its results for the 18-month period ending December 31 in the first quarter of 2023. Its interim results for the year ended June 30 will be published in September.
Current stock price: 10.53 pence, up 2.7% in London on Tuesday
12-month change: down 83%
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.